Abstract
Tumor-infiltrating lymphocytes (TIL) are associated with survival in virtually every human cancer studied, but the mechanisms by which they confer protective immunity remain incompletely understood. Focusing on ovarian cancer, our group applies genomic and molecular pathology approaches to define the mechanisms by which the immune system responds to the evolving tumor genome over space and time. We have shown that optimal anti-tumor immunity involves interactions between T cells and antibody-producing B cells and plasma cells in the tumor microenvironment. Moreover, we have identified three patterns of TIL response in ovarian cancer, each carrying distinct implications for immunotherapy. We are translating these insights into clinical trials involving adoptive transfer of tumor-reactive T cells.
Highlights
Customizing cancer immunotherapies to match the intrinsic tumor microenvironment
This article is published with open access by BioMedPress (BMP)
Our group applies genomic and molecular pathology approaches to define the mechanisms by which the immune system responds to the evolving tumor genome over space and time
Summary
Customizing cancer immunotherapies to match the intrinsic tumor microenvironment Director and Distinguished Scientist, Deeley Research Centre, BCCA Professor, Biochemistry and Microbiology, UVIC Adjunct Professor, Biology, UVIC; Professor, Medical Genetics, UBC Canada
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have